SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Synageva BioPharma Corp.
02 Junho 2015 - 8:29PM
Business Wire
Law office of Brodsky & Smith, LLC announces that it is
investigating potential claims against the Board of Directors of
Synageva BioPharma Corp. ("Synageva” or "the Company") (Nasdaq:
GEVA) for possible breaches of fiduciary duty and other violations
of state law in connection with the sale of the Company to Alexion
Pharmaceuticals, Inc. (“Alexion”).
Click here to learn more about the investigation
http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or
call: 877-534-2590. There is no cost or obligation to you.
Under the terms of the transaction, Synageva shareholders will
receive only 0.6581 of an Alexion share and $115.00 in cash for
each share of Synageva stock they own. The transaction values
Synageva at only approximately $225.92 per share. The investigation
concerns whether the Board of Synageva breached their fiduciary
duties to shareholders and whether Alexion is underpaying for
Synageva. The transaction may undervalue Synageva as the Company
has a strong pipeline of protein therapeutic programs for patients
with rare diseases who have unmet medical needs. This includes
Kanuma, for the treatment of Lysosomal Acid Lipase Deficiency. In
addition, an analyst has placed a $230.00 per share price target on
Synageva stock.
If you own shares of Synageva and wish to discuss the legal
ramifications of the investigation, or have any questions, you may
e-mail or call the law office of Brodsky & Smith, LLC who will,
without obligation or cost to you, attempt to answer your
questions. You may contact Jason L. Brodsky, Esquire or Evan J.
Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
510, Bala Cynwyd, PA 19004, by visiting
http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or
calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive
expertise representing shareholders throughout the nation in
securities and class action lawsuits. The attorneys at Brodsky
& Smith have been appointed by numerous courts throughout the
country to serve as lead counsel in class actions and have
successfully recovered millions of dollars for our clients and
shareholders. Attorney advertising. Prior results do not guarantee
a similar outcome.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150602007080/en/
Brodsky & Smith, LLCJason L. Brodsky, EsquireEvan J. Smith,
Esquire877-LEGAL-90http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html
(MM) (NASDAQ:GEVA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
(MM) (NASDAQ:GEVA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Synageva Biopharma Corp. (MM)